[sci.med.aids] HICN 329 News -- excerpts.

dmcanzi@watserv1.waterloo.edu (David Canzi) (08/18/90)

               Medical News for July 30, 1990 to August 13, 1990
        Copyright 1990: USA TODAY/Gannett National Information Network

                                      ---
                                 July 31, 1990
                                      ---

                            AIDS FROM TRANSFUSIONS:

   Some experts believe up to 460 people a year were  infected  with  the  HIV
virus  as  recently  as 1988.  Blood bankers now say the blood supply is safer
than ever and that no one should forego a necessary transfusion out  of  fear.
And  a  congressional investigation has been launched to determine whether the
blood industry responded properly during the early AIDS epidemic.

                                      ---
                                 Aug. 1, 1990
                                      ---

                              HIV CASES ESCALATE:

   The World Health Organization now estimates that 8 million  to  10  million
people worldwide are infected with HIV, the virus that causes AIDS. The figure
is  up  from  an  earlier  estimate  of  6 million to 8 million infections and
reflects the escalating epidemic in the developing world,  WHO officials  say.
U.S.  health officials estimate that there are 1 million HIV infections in the
USA.

                           AIDS INFECTIONS TARGETED:

   A new push to find treatments for the variety of  infections  that  afflict
AIDS  patients  will  be announced at a congressional hearing Wednesday by the
National Institute of Allergy and Infectious Diseases.  The AIDS  virus,  HIV,
breaks  down  the  immune  system  and causes up to 90 percent of AIDS-related
deaths.  Under the new program,  six research teams will share $2.8 million in
grants.

                                      ---
                                 Aug. 2, 1990
                                      ---

                           BLOOD IS SAFER THAN EVER:

   Since 1985,  the addition of the HIV antibodies test,  along with tests for
hepatitis  C and a rare virus called HTLV-1,  have made blood safer than ever,
say medical experts.  Adding to safety:  More surgery  patients  now  get  the
option  of  donating  their  own  blood,  thus eliminating the risk.  And many
physicians have cut blood use,  turning to  transfusions  only  when  benefits
outweigh risks.

                                      ---
                                 Aug. 8, 1990
                                      ---

                        BLOOD BANKS SAY SUPPLY IS SAFE:

   Blood  banks  say  the  nation's  supply  is safer than ever,  but a recent
lawsuit charging negligence in screening,  before the AIDS test was  developed
in  1985,  has  thrown  the problem into the spotlight again.  And while AIDS-
tainted blood transfusions are extremely rare today,  thousands of people were
getting a lethal form of hepatitis from tainted blood until this year.

                                      ---
                                 Aug. 9, 1990
                                      ---

                        BLOOD BANKS SHUN NEW AIDS TEST:

   Blood  banks  will  not routinely use a new test that can detect a rare and
distinct form of the AIDS-causing virus,  which can slip past standard  tests.
Cited:  a  national  annual  cost of $15 million.  Large scale tests for HIV-2
have shown no evidence of transmission in the United States,  says Dr.  Thomas
O'Brien for the Centers for Communicable Diseases in Atlanta.

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
                      Center for Disease Control Reports
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

                     Morbidity and Mortality Weekly Report
                           Thursday  August 2, 1990

     Characteristics of Clients in Alcohol and Drug-Treatment Centers --
                             South Carolina, 1989

    The South Carolina Department of Health and Environmental Control (SCDHEC)
recently  evaluated  characteristics  of clients in detoxification programs of
selected alcohol-  and  drug-treatment  centers  to  determine  1)  the  human
immunodeficiency  virus  (HIV),  hepatitis  B,  and syphilis seropositivity of
clients;  2) the proportion of clients with histories of intravenous (IV)-drug
use;  and  3) clients' drug-use and risk behaviors and attitudes.  This report
presents findings of the SCDHEC evaluation.
    In 1989,  the  37  public,  community-based  alcohol-  and  drug-treatment
centers in South Carolina served 32,323 clients who had a primary diagnosis of
alcohol  or  other  drug use.  In South Carolina,  clients who are admitted to
alcohol- and drug-treatment centers are charged  for  services  on  a  sliding
scale  based on their ability to pay;  no one is refused service.  Clients are
referred for treatment by themselves, state and local agencies, hospitals, and
emergency rooms.  Inpatient services are offered for a  maximum  of  28  days;
outpatient  services may continue indefinitely.  In 1989,  86% of clients were
treated on an outpatient basis.
    From April 25 through June 23,  1989,  the SCDHEC surveyed and tested  all
clients  entering  detoxification  services  at  alcohol-  and  drug-treatment
centers in three  urban  counties  (approximate  population  of  each  county:
300,000).  During this period, 632 clients entered the centers and were tested
for HIV,  hepatitis B surface antigen  (HBsAg),  and  syphilis  (rapid  plasma
reagin  (RPR));  nine  (1%)  were  HIV-antibody  positive,  21 (3%) were HBsAg
positive, and 22 (3%) had a reactive RPR.
    Of the 632 clients,  478 (76%) completed an  anonymous,  self-administered
questionnaire  concerning  drug  use,  HIV-transmission  risk  behaviors,  and
attitudes  regarding  HIV  prevention.   Of  the  clients  who  completed  the
questionnaire,  442 (92%) provided drug-use information.  Of these,  182 (41%)
indicated they had used IV drugs at some time  in  the  past,  and  129  (29%)
indicated  they had used IV drugs in the past year.  The median age of the IV-
drug users (IVDUs) was  31  years  (range:  12-72  years),  and  their  median
education level was 12th grade (range:  4-16 years of school).  Of the 174 for
whom gender was known,  131 (75%) were male.  Of the 169  for  whom  race  was
known,  103 (61%) were white,  63 (37%) were black,  and three (2%) were other
races.  Sexual preference was known for 163 IVDUs: 150 (92%) were heterosexual
and 13 (8%;  nine males and four females) were homosexual/bisexual.  Drug  use
was reported by the nine HIV-positive persons:  seven indicated IV-drug use as
their only  risk  behavior,  one  indicated  a  history  of  IV-drug  use  and
bisexuality, and one indicated a history of non-IV cocaine use.
    Of  the  182  clients  who  had  used IV drugs,  80 (44%) reported sharing
needles or other drug-injection equipment.  One hundred  six  (58%)  indicated
that  they  always  rinsed their drug-injection equipment after use;  however,
only 16  (15%)  of  these  used  bleach  when  cleaning  their  drug-injection
equipment.  Of  the 182 IVDUs,  28 (15%;  16 males,  10 females,  two unknown)
indicated that in the past year they had exchanged sex for  money,  drugs,  or
other  gifts.  The  drugs most frequently injected were cocaine (62%),  heroin
(30%), and combinations of cocaine and heroin (22%).
    Of 114 persons indicating how frequently they  injected  drugs,  43  (38%)
reported injecting daily; 34 (30%), weekly; and 37 (32%), monthly.  Of the 173
persons who answered questions on condom use,  88 (51%) reported  never  using
condoms; 72 (42%), sometimes using condoms; and 13 (8%), always using condoms.
    In regard to attitudes about HIV testing,  85% of the IVDUs indicated that
all persons  in  a  drug-treatment  program  should  be  offered  testing  and
counseling at the site where drug treatment is received.

Reported by:  JL Jones,  MD,  P Rion,  MSPH, H Dowda, PhD, L Kettinger, MPH, R
Ball, MD,  WB Gamble,  Jr,  MD,  State Epidemiologist,  South Carolina Dept of
Health and Environmental Control.  L Nalty, MHEd, D Nalty, PhD, South Carolina
Commission on Alcohol and Drug Abuse.  Editorial Note:  The findings  of  this
evaluation  by  the SCDHEC have played an important role in the development of
new disease-prevention programs in South Carolina alcohol- and  drug-treatment
centers.  These  programs  include  client  education on the prevention of HIV
infection,  hepatitis B,  and sexually  transmitted  diseases;  specific  HIV-
training  sessions  for  substance-abuse  counselors;  training  plans for the
implementation of outreach  programs;  specific  risk-reduction  programs  for
female  IVDUs;  condom distribution programs;  and a program for counselors to
demonstrate one-on-one to clients how to clean drug-injection  equipment  with
bleach.
    This  survey (which involved 76% of clients) found that 41% of the clients
of these centers reported IV-drug use.  Clients who attend alcohol- and  drug-
treatment centers may not be representative of the IV-drug-using population in
a  locality  (1);  however,  they do represent a population that is accessible
through public health programs that offer counseling and testing for  HIV  and
other  sexually  transmitted  diseases,  partner notification,  and other HIV-
related services (e.g.,  free and confidential  CD4  lymphocyte  testing  with
referral   to  other  health-care  providers).   These  services  can  provide
incentives for clients to return for follow-up counseling,  which is important
for  behavioral  change  among  IVDUs  (2).  Results  of  this evaluation also
indicate that greater efforts in preventive education  are  needed  to  reduce
risk factors associated with HIV transmission among IVDUs.

References

1.  CDC.  Coordinated community programs for HIV prevention among intravenous-
drug users--California, Massachusetts. MMWR 1989;38:370-4.

2.  van den Hoek JAR,  van Haastrecht HJA,  Coutinho RA.  Risk reduction among
intravenous-drug  users in Amsterdam under the influence of AIDS.  Am J Public
Health 1989;79:1355-7.

                     Morbidity and Mortality Weekly Report
                           Thursday  August 9, 1990

    Update: Reducing HIV Transmission in Intravenous-Drug Users Not in Drug
                          Treatment -- United States

    In 1987,  the National Institute on Drug Abuse  (NIDA)  initiated  ongoing
demonstration  projects  to  study  and change the high-risk behaviors of both
intravenous-drug users (IVDUs) who were not enrolled  in  drug  treatment  and
their sex partners (1). The goal of the projects is to eliminate or reduce the
likelihood  of  human immunodeficiency virus (HIV) transmission from these two
high-risk groups.  As of July 1,  1990,  the projects  included  greater  than
30,000  IVDUs  and  their  sex  partners in 41 community-based programs.  This
report describes preliminary data (as of  January  1990)  based  on  follow-up
interviews  of  1584  primarily  less  than  40-year-old,  black,  male  IVDUs
recruited from 1987 through 1989 in Chicago, Houston, Miami, Philadelphia, and
San Francisco (Table 1, page 535).
    In these projects,  IVDUs were recruited through community-based  outreach
workers  who  were  familiar  with  the  neighborhoods  in  which the programs
operate,  were often former drug users,  and had access  to  neighborhoods  in
which  drugs  were  used.   Eligibility  criteria  for  participants  included
intravenous (IV)-drug use during  the  6  months  before  recruitment  and  no
enrollment  in a drug-treatment program during the 30 days before recruitment.
Clients were paid for their participation.  The return rates for  participants
from  initial  to  follow-up interviews were greater than 65% in four cities--
ranging from 45% (Houston) to 78% (Philadelphia).
    The specific interventions to reduce risk behaviors  varied  by  city  but
included one or more of the following:  1) individual and group counseling, 2)
efforts to build peer support for behavior change, and/or 3) demonstration and
practice  of  behaviors  that  reduce  risk.   All  interventions   emphasized
termination  of IV-drug use.  IVDUs were urged to start drug treatment as soon
as it  became  available  to  them.  In  all  cities,  the  programs  strongly
encouraged  those  who  did  not  stop  IV-drug  use  to 1) stop sharing drug-
injection equipment (e.g., needles and syringes, drug-cooking implements,  and
rinse water); 2) use only sterile needles and syringes from unopened packages;
and/or  3) disinfect drug-injection equipment with bleach or other appropriate
agents.  The interventions related to sexual activity advocated celibacy  and,
for persons who were sexually active, safer sexual practices, including use of
condoms and reduction of the number of sex partners.
    Fourteen  percent  to  35%  of  IVDUs participating in the first follow-up
interview had entered a drug-treatment  program  during  the  approximately  6
months after enrollment (Table 1). Forty-nine percent to 75% of IVDUs reported
stopping   or   decreasing  their  frequency  of  drug  injection  during  the
approximately  6  months  between  the  initial  intervention  and   follow-up
interview  (Table  1)--including  16%-47%  who reported stopping all use of IV
drugs.(Continued on page 535)
    In all five cities, the percentage of IVDUs who reported not sharing drug-
injection equipment with friends  increased  in  the  approximately  6  months
between  initial and follow-up interviews,  as did the percentage of IVDUs who
reported not borrowing previously used  drug-injection  equipment  (Table  1).
Thirty-four  percent  (Houston)  to  59% (Chicago) of IVDUs reported decreased
sharing of drug-injection equipment;  22% (San Francisco) to 37% (Chicago)  of
IVDUs reported decreased borrowing of drug-injection equipment.
    Of those who continued to inject drugs at follow-up,  except for those who
reported always using new needles,  20%-39% of IVDUs reported increased use of
bleach for cleaning drug-injection equipment (Table 1).  Eleven percent to 43%
of IVDUs reported consistent use of bleach.
    Regular condom use with a steady sex partner increased in three cities  to
12%-16% (Table 2).  Regular condom use with multiple sex partners increased in
four cities to 10%-27%.

Reported by:  MY Iguchi, PhD, School of Osteopathic Medicine, Univ of Medicine
and  Dentistry of New Jersey,  Camden,  New Jersey.  J Watters,  PhD,  Univ of
California,  San  Francisco;   P  Biernacki,  PhD,   Youth  Environment  Study
Corporation, San Francisco, California.  CB McCoy, PhD, DD Chitwood, PhD, Univ
of Miami, Florida. W Wiebel, PhD, Univ of Illinois, Chicago.  J Liebman, MS, L
Kotranski,  PhD,  Philadelphia Health Management Corporation, Pennsylvania.  M
Williams, PhD, Affiliate Systems Corporation, Houston, Texas.  BS Brown,  PhD,
National  Institute  on  Drug Abuse,  Alcohol,  Drug Abuse,  and Mental Health
Administration.  Office of the Director, Center for Prevention Svcs, CDC.

Editorial Note:  IV-drug use is an important factor in the transmission of HIV
(2).  Of  the  117,781  persons with acquired immunodeficiency syndrome (AIDS)
reported in the United States in 1989,  36,356 (30.8%) are in a  risk-behavior
category directly or indirectly related to IV-drug use (3).
    IVDUs  are difficult to reach and influence with traditional public health
education and other  prevention  interventions  (4).  Although  drug-treatment
centers  can  serve the dual purpose of drug treatment and HIV prevention,  an
estimated 80% of active IVDUs are not in treatment  (National  Association  of
State Alcohol and Drug Abuse Directors, unpublished data).  New approaches and
more effective strategies for reaching IVDUs not in drug treatment are  needed
to decrease drug use and stem the HIV epidemic.
    These  preliminary  results,  which show an overall reduction in high-risk
behaviors of IVDUs,  suggest that participation in outreach  and  intervention
programs  can  influence  entry  into drug-treatment programs and reduce drug-
injection behaviors associated with increased risk for HIV  transmission.  The
lowest  rates  for  IVDUs  entering  drug-treatment programs were in Miami and
Houston,  where capacities of  publicly  funded  drug-treatment  programs  are
limited. Stronger evidence of the considerable impact that this approach could
have if implemented nationwide would be provided if the results at other sites
prove to be consistent with these preliminary results.
    A  related  study  in  San  Francisco  (5) suggests that outreach programs
affect even the behaviors of IVDUs in the community who  did  not  participate
directly  in  the interventions.  Cross-sectional samples of approximately 500
IVDUs recruited at 6-month intervals during 1986 and 1989  revealed  that  the
introduction of outreach programs to IVDUs in 1986 corresponded with the start
of communitywide increases in bleach use (from 3% in 1986 to 86% in 1989).
    The Health Behavior Projects in Newark and Jersey City,  New Jersey,  have
shown that IVDUs can be recruited directly from the street  and  community  to
enter drug-treatment programs when drug treatment is made more accessible.  In
these projects,  49% of 1884  IVDUs  who  participated  in  intake  interviews
subsequently  entered  21- or 90-day methadone treatment programs at no charge
(M.Y. Iguchi, unpublished data, 1990).
    The results reported here reflect the  effectiveness  of  street  outreach
combined  with additional behavior-change interventions such as HIV counseling
and testing.  An additional strength  of  the  projects  may  be  the  use  of
nontraditional  outreach workers to recruit IVDUs into treatment.  As in other
studies (4),  reported reductions in drug-use risk behaviors were larger  than
reductions in sexual risk behaviors.
    Recruiting  drug  users  into and keeping them in well-managed,  effective
drug-treatment programs can reduce risk behaviors for HIV infection (6).  This
strategy   is  essential  to  all  HIV-prevention  programs  for  drug  users.
Additional strategies  are  needed  to  reach  drug  users  not  in  treatment
programs.  Since  peers  may  influence former drug users to use drugs,  drug-
treatment and HIV-prevention programs  need  to  provide  long-term,  repeated
contacts with IVDUs who have returned to the community after drug treatment.
    Street/community  outreach  is  an  important  element  of a comprehensive
program to reach IVDUs in a  variety  of  settings  (including  drug-treatment
centers,  public  health  clinics,  free-standing  HIV  counseling and testing
programs,   correctional  facilities,   and  health-care  facilities  such  as
hospitals  and emergency rooms) and is best coordinated at the community level
to assure maximum coverage and effectiveness (7).  Project TRUST in Boston (8)
and  South Carolina's survey of clients in alcohol- and drug-treatment centers
(9) are efforts to meet the  specific  needs  of  IVDUs  for  HIV  prevention.
Continuous  reassessment  is important in determining how outreach can be most
effectively used in HIV and drug-treatment programs.

References

1.  CDC.  Risk behaviors for HIV transmission among intravenous-drug users not
in drug treatment--United States, 1987-1989. MMWR 1990;39:273-6.

2.  CDC.  HIV/AIDS surveillance report.  Atlanta:  US Department of Health and
Human Services, Public Health Service, January 1990:9.

3.  CDC.  HIV/AIDS surveillance report.  Atlanta:  US Department of Health and
Human Services, Public Health Service, July 1990:8.

4.  Turner CF, Miller HG, Moses LE, eds.  AIDS sexual behavior and intravenous
drug use. Washington, DC: National Academy Press, 1989.

5.  Watters JK, Cheng Y, Segal M, Lorvick J, Case P,  Carlson J.  Epidemiology
and  prevention  of HIV in intravenous drug users in San Francisco,  1986-1989
(Abstract).  Vol 2.  VI International Conference on AIDS.  San Francisco, June
20-24, 1990:116.

6.  Hartel D,  Selwyn PA,  Schoenbaum EE,  Klein RS,  Friedland GH.  Methadone
maintenance treatment (MMTP)  and  reduced  risk  of  AIDS  and  AIDS-specific
mortality   in  intravenous  drug  users  (IVDUs)  (Abstract).   Book  2.   IV
International Conference on AIDS. Stockholm, June 12-16, 1988:395.

7.  CDC.  Coordinated community programs for HIV prevention among intravenous-
drug users--California, Massachusetts. MMWR 1989;38:369-74.

8.  CDC.  Counseling  and  testing  intravenous-drug users for HIV infection--
Boston. MMWR 1989;38:489-90,495-6.

9.  CDC.  Characteristics of clients in alcohol- and drug-treatment  centers--
South Carolina, 1989. MMWR 1990;39:519-20.

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Volume  3, Number 29                                          August 13, 1990

              +------------------------------------------------+
              !                                                !
              !              Health Info-Com Network           !
              !                    Newsletter                  !
              +------------------------------------------------+
                         Editor: David Dodell, D.M.D.
                   St. Joseph's Hospital and Medical Center
    10250 North 92nd Street, Suite 210, Scottsdale, Arizona 85258-4599 USA
                          Telephone +1 (602) 860-1121
                              FAX +1 (602) 451-1165

   Copyright 1990 - Distribution on Commercial/Pay Systems Prohibited without
                              Prior Authorization

The Health Info-Com Network Newsletter is distributed weekly.  Articles  on  a
medical  nature  are  welcomed.  If  you  have an article,  please contact the
editor for information on how to submit it.  If you are interested in  joining
the automated distribution system, please contact the editor.

E-Mail Address:
                                    Editor:
                              FidoNet = 1:114/15
                           Bitnet = ATW1H @ ASUACAD
                     Internet = ddodell@stjhmc.fidonet.org
      LISTSERV = MEDNEWS @ ASUACAD.BITNET (or internet: asuvm.inre.asu.edu)
                         anonymous ftp = vm1.nodak.edu
       (Notification List/ftp = hicn-notify-request@stjhmc.fidonet.org)

Associate Editors:

o   Dr. Bruce MacDougall, University of Massachusetts at Amherst
       (Bitnet: BRUCEMA@UMASS)
o   Dr. J. Martin Wehlou (Bitnet: WEHLOU@BGERUG51)

-- 
David Canzi